Leflunomide versus methotrexate in Wegener's granulomatosis

Rheumatology

Volumn 46, Issue 7, 2007, Pages 1047-1048

  Jayne, D ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; CAMPATH 1 H; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOGLOBULIN; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; RITUXIMAB; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDITORIAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LONG TERM CARE; LYMPHOCYTE DEPLETION; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; RISK REDUCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; METHOTREXATE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; REMISSION INDUCTION; WEGENER GRANULOMATOSIS;

EID: 34447302857     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem050     Document Type: Editorial

References (29)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
2. Watts RA, Scott DG. Epidemiology of the vasculitides. Semin Respir Crit Care Med 2004;25:455-64.
3. Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med 1971;285:1493-6.
4. Hellmich B, Flossmann O, Gross WL et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: Focus on ANCA-associated vasculitis. Ann Rheum Dis 2006;14:14.
5. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006;70:938-47.
6. Sanders JS, Huitma MG, Kallenberg CG, Stegeman CA. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology 2006;45:724-9.
7. Sanders JS, Stassen PM, van Rossum AP, Kallenberg CG, Stegeman CA. Risk factors for relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: Tools for treatment decisions? Clin Exp Rheumatol 2004;22:S94-101.
8. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
9. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005;352:330-2.
10. Popa ER, Stegeman CA, Bos NA, Kallenberg CG, Tervaert JW. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin Exp Immunol 2003;132:496-504.
11. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, de Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994;120:12-7.
12. Pagnoux C, Mahr A, Cohen P et al. Treatment of ANCA-associated vasculitis: Corticosteroids and pulse cyclophosphamide followed by maintenance therapy with methotrexate or azathioprine. Ann Rheum Dis 2006;64(Suppl. 3):246.
13. De Groot K, Rasmussen N, Bacon PA et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:2461-9.
14. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002;47:326-32.
15. de Groot K, Reinhold-Keller E, Tatsis E et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/ sulfamethoxazole. Arthritis Rheum 1996;39:2052-61.
16. Koukoulaki M, Jayne DR. Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006;102:100-7.
17. Stassen PM, Cohen Tervaert JW, Stegeman CA. Induction of remission in active ANCA-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2006;19:19.
18. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology 2004;43:315-20.
19. Jayne DR. Conventional treatment and outcome of Wegener's granulomatosis and microscopic polyangiitis. Cleve Clin J Med 2002;69:SII110-5.
20. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
21. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996;335:16-20.
22. Hale G. Recent developments in humanized MAbs for immunotherapy: A personal tribute to Dr. Martin Lockwood. Transfus Sci 1999;21:181-4.
23. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, van der Woude FJ. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients. Kidney Int 2004;65:1440-8.
24. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
25. Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: Report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-7.
26. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004;15:717-21.
27. Jayne DR, Chapel H, Adu D et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000;93:433-9.
28. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004;63:1649-54.
29. Schmitt WH, Birck R, Heinzel PA et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: An open study in seven patients. Nephrol Dial Transplant 2005;20:1083-92.